Literature DB >> 14562822

Should ACE inhibition always be first-line therapy in heart failure? Lessons from the CARMEN Study.

Willem J Remme.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14562822     DOI： 10.1023/a:1025324516325

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


× No keyword cloud information.
  3 in total

1.  Surgical ventricular restoration: the RESTORE Group experience.

Authors:  Constantine L Athanasuleas; Gerald D Buckberg; Alfred W H Stanley; William Siler; Vincent Dor; Marisa DiDonato; Lorenzo Menicanti; Sergio Almeida de Oliveira; Friedhelm Beyersdorf; Irving L Kron; Hisayoshi Suma; Nicholas T Kouchoukos; Wistar Moore; Patrick M McCarthy; Mehmet C Oz; Francis Fontan; Meredith L Scott; Kevin A Accola
Journal:  Heart Fail Rev       Date:  2004-10       Impact factor: 4.214

2.  Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study.

Authors:  S K Prasad; H J Dargie; G C Smith; M M Barlow; F Grothues; B A Groenning; J G F Cleland; D J Pennell
Journal:  Heart       Date:  2005-12-09       Impact factor: 5.994

3.  ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C ? : editorial to: effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.

Authors:  Rudolf A de Boer; Dirk J van Veldhuisen
Journal:  Cardiovasc Drugs Ther       Date:  2008-04-17       Impact factor: 3.727
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.